Johnson & Johnson (JNJ) continues to stand out as a premier choice for retirees seeking reliable income through dividend stocks, boasting an impressive 63-year streak of annual dividend increases. This remarkable achievement positions J&J as a Dividend King within the healthcare sector, far surpassing its peers, including AbbVie and Abbott, which have 54 years of increases. The company’s strong business model and diversified operations, particularly following the spin-off of its consumer products division into Kenvue, reinforce its stability.
The significance of J&J’s dividend history lies in its ability to provide consistent income amidst market fluctuations. With nearly two-thirds of its revenues derived from its pharmaceutical business and a robust medical device segment, J&J mitigates risks associated with patent expirations in the drug industry. Despite a yield of approximately 2.2%, which is below the 4% target for many dividend investors, its AAA credit rating assures that dividends are well-supported financially.
For market professionals, J&J represents a compelling option for income-oriented portfolios, especially given its long-standing commitment to dividend growth and operational diversification.
Source: fool.com